Explore our company news, announcements and updates
December 4, 2025
FDA Conditionally Approves MSD Animal Health’s EXZOLT™ CATTLE-CA1 for the Prevention and Treatment of New World Screwworm (Cochliomyia hominivorax) Larvae (myiasis)
Mexico’s SADER Approves MSD Animal Health’s EXZOLT® 5% Pour-On (Fluralaner 50 mg/mL) for the Prevention and Treatment of New World Screwworm (Cochliomyia hominivorax) Larvae (Myiasis)
New Data from MSD Animal Health Demonstrates that Intranasal Vaccination Against Bovine Coronavirus with BOVILIS® NASALGEN®-C (Lyophilisate and Solvent for Suspension for Cattle) Significantly Improves Production in Veal Calves
MSD Animal Health Presents New Data Demonstrating the Safety, Efficacy and Quick Onset of Injectable Formulation of BRAVECTO® (fluralaner) at World Small Animal Veterinary Association Congress
MSD Animal Health Presented New Data on NUMELVI® (atinvicitinib) Tablets for Dogs and MOMETAMAX ULTRA® (gentamicin, posaconazole, and mometasone furoate otic suspension) for Dogs at the 2025 European Veterinary Dermatology Congress
MSD Animal Health Presents New Data Highlighting Commitment to the Development and Study of Parasite Prevention and Treatment for Dogs at the 2025 World Association for the Advancement of Veterinary Parasitology Congress
